The additional modification of Asn1 of the GALR2-specific agonist significantly increased the stability of the peptides in serum, allowing possible clinical applications for GALR2-mediated disorders or diseases, such as anxiety, depression, and obesity, as these molecules are known to play important roles in these processes. Here, GALR2 is linked to major depressive disorder.